Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine

John H. Stewart IV, Steven A. Rosenberg

Research output: Contribution to journalArticlepeer-review

Abstract

Immunization with the modified gp 100 melanoma peptide gp 100:109-217 (210M) in Incomplete Freund's Adjuvant (IFA) results in the generation of anti-peptide and antitumor lymphocytes in the patients' circulation. In this study, the authors have evaluated the persistence of these immune cells. Reactivity against the native peptide persisted for 138 to 403 days after immunization. Reactivity also persisted in throe of five patients that received external beam radiotherapy and in both patients who received systemic chemotherapy after the completion of peptide immunization. Thus, immune lymphocytes with anti gp100:209-217 peptide activity appear to persist for prolonged periods after vaccination with modified peptide in IFA.

Original languageEnglish (US)
Pages (from-to)401-404
Number of pages4
JournalJournal of Immunotherapy
Volume23
Issue number4
DOIs
StatePublished - Jul 2000

Keywords

  • G209-2M
  • Melanoma

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine'. Together they form a unique fingerprint.

Cite this